Chiglitazar, an orally available small molecule pan-PPAR agonist (i.e., simultaneous activation of PPARα, δ, and γ), has shown efficacy in the treatment of type 2 diabetes and nonalcoholic steatohepatitis 19. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.